Targeted therapies for renal cell carcinoma: review of adverse event management strategies. - Wikidata - thesis-toulmin - TriplyDB

Targeted therapies for renal cell carcinoma: review of adverse event management strategies.

Targeted therapies for renal cell carcinoma: review of adverse event management strategies.

http://www.wikidata.org/entity/Q37974894

about

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer Safety and tolerability of pazopanib in the treatment of renal cell carcinoma Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma.The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma.Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.Life-threatening gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a case report.CTR1 silencing inhibits angiogenesis by limiting copper entry into endothelial cells.Meta-analysis identifies NF-κB as a therapeutic target in renal cancer.Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma.Experience with sunitinib in the treatment of metastatic renal cell carcinoma Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.Uncommon gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: A report of four cases Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.Ovatodiolide Targets β -Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma.Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.Adjuvant therapy in renal cell carcinoma-past, present, and future.Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma Acute Hyperglycemia Associated with Anti-Cancer Medication.Temsirolimus: a safety and efficacy review.Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition.Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.Tivozanib for the treatment of metastatic renal cancer.

P2860

Q26741153-8FBF207A-2191-48DE-85BC-6A26D9DD31CA Q26821956-95FF7BB3-E6D9-4A82-8494-97036F638670 Q28272429-B132CFAC-A905-4588-B3CC-FC2E8B1FED29 Q30243969-F0B7BD6A-6127-4408-8B51-E8C2605BC21B Q33408049-9D51B5AB-7F4C-4770-8436-1995AF88D0E4 Q33408085-5F299B3B-6B0E-4EFC-948C-8393BAEE72BC Q33432282-CE0F4C98-E5B9-40A8-B048-45569EA66B7B Q33776408-2846AE4A-4BC2-4AB2-9A26-493DD71BD5AE Q34272770-CF6D7C2A-E1E5-4139-B81E-43E3B98508C3 Q34507381-92FF5447-7CFB-48AE-9D45-9C8D35264B64 Q34658095-38E8B476-8DAE-4F78-9A8D-87DBB0BED222 Q34809995-02C9D834-AD13-4E2B-B3D2-0DF0821113A1 Q34988260-818E86F4-523B-45B6-82A4-E6D4C6CB1582 Q35014835-B5D00BB9-3014-4D5D-903F-801F77CFA93D Q35052033-6121F464-5B18-45A9-A747-50124C1BBEC6 Q36197132-0FB881D0-C21C-49D0-ADF2-ED34A9C444D9 Q36231729-1CCBB652-80F2-4F95-B42D-F85C92E92185 Q36252946-7944604E-673E-4B4A-B903-8C8A30193659 Q36281483-D67E1707-3898-427A-9F04-27249611F1FA Q36336354-D731E4BC-3EFA-4986-922A-4B09A443B832 Q36546814-0A388DCD-C7D7-4394-80C8-108981F33D8A Q36709236-06D366BF-42E1-4040-B2A3-07330EC60F37 Q36890998-591128AB-8DBF-4DDD-B0F0-1DAD2A2B44EB Q36916021-58811D54-2E2E-4250-A5C8-7C80AE13D644 Q36959193-DE5383FE-3E90-4B7B-9B04-9CD14EFCFBD5 Q37117596-DA3E0DB9-69DF-44AC-8C3E-D9A0D7A4696D Q37153437-69880C6C-CE43-4262-A181-C654B5DB1B71 Q37274320-66C31148-FDEF-448A-8599-72986F22DEB9 Q37577963-4707124B-EFB9-4AAF-B64D-06396B6C8915 Q37644821-978E6341-6703-4D59-BF78-20035E7405AE Q37681761-F926BC68-65D0-4C36-A375-2A1EC8D9546A Q37723241-5DCE3076-6BF5-4389-9802-443465561063 Q38031941-40381570-08DF-433B-BB5E-7592DB2FF492 Q38059507-B38071D0-837A-4DB7-8827-F70CDE06EDFD Q38065993-029A0F89-D8E2-4F20-903F-414490EAB9E6 Q38068584-502735C5-B70C-41D0-9884-F2DE361688CB Q38068586-20F4F486-E4F3-4541-85B4-36DE5FC9FD73 Q38071132-6C4F5E7F-DB18-46B7-818B-F8B43B103197 Q38074121-CC55A011-8CD4-444F-815A-FF9BA86FC473 Q38114944-06C721A1-74E7-4A2A-8F4D-0EA5F7D08BAC

P2860

Targeted therapies for renal cell carcinoma: review of adverse event management strategies.

http://www.wikidata.org/entity/Q37974894

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Targeted therapies for renal c ...... e event management strategies.

@en

Targeted therapies for renal c ...... e event management strategies.

@nl

type

label

Targeted therapies for renal c ...... e event management strategies.

@en

Targeted therapies for renal c ...... e event management strategies.

@nl

prefLabel

Targeted therapies for renal c ...... e event management strategies.

@en

Targeted therapies for renal c ...... e event management strategies.

@nl

P1433

Q37974894-EEB4E99F-BD75-45B3-9D02-B03D1D2D7624

P1476

Q37974894-229DB1B2-3C39-4F4A-8097-0789D05E4225

P2093

Q37974894-1B94DDE8-B517-4A96-841F-C200077AFB8F

Q37974894-24A51A39-6925-4EAC-85D4-BAE1BC152C11

Q37974894-36E944CD-AE55-4B08-845A-4D304F747FF2

Q37974894-6E0BBF53-4976-4185-B71A-3B09FC7B4F64

Q37974894-7E82F0DD-D079-49A2-9928-7D6F05CA0CCA

Q37974894-E4B041B5-8409-4967-850C-977A809EBB0E

P2860

Q37974894-0366B0A2-375A-494F-97A9-31B3A913B554

Q37974894-03D2537B-F89D-4CC5-89C8-F96F95B9FB4C

Q37974894-067C537B-4F4E-4D0A-8B47-8B5FB3678F57

Q37974894-0A2B0433-4743-4D36-941D-F628B469807A

Q37974894-0CDA2C92-2DDD-4744-A386-1109E08D2221

Q37974894-1508A906-677E-4A55-BF29-8AD506711CC2

Q37974894-16070AAF-5636-49F2-8900-8F70B93608B0

Q37974894-19D13693-B12A-427B-AC8A-C95270716D29

Q37974894-1AD32C07-3D13-4A3A-94F3-DC5E2C6C0336

Q37974894-1B5326DB-4409-4C1F-A310-59C51948BA79

P304

Q37974894-38D6431E-D100-4A63-A580-85C9CB0A84A2

P31

Q37974894-C8ED487A-406D-4486-B653-0DD81202F711

P356

Q37974894-6953DF74-824F-403B-ACB9-A96AD1C3AD97

P407

Q37974894-6F345A28-7864-4436-A40A-8AAB12967D35

P433

Q37974894-AF5A4DFA-A69D-426B-A947-1862A85BCC81

P478

Q37974894-FBA862AF-294B-424C-8AB7-8A6A1CA10E81

P50

Q37974894-1EEF2268-DE2D-4CB7-BB1B-4633F8E0CCC6

Q37974894-3D961E18-ECFF-490B-A45E-BD77BE855D0C

P577

Q37974894-9A254248-DC87-401B-A18C-5C0590E86965

P5875

Q37974894-040AB8D1-E083-4F11-8DDA-2FF1D323BECF

P698

Q37974894-15BA9C6B-B141-40DE-A218-E117DFE9BD92

P356

P1433

Journal of the National Cancer Institute

P1476

Targeted therapies for renal c ...... e event management strategies.

@en

P2093

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Hassan Izzedine

http://www.w3.org/2001/XMLSchema#string

Lynda Pyle

http://www.w3.org/2001/XMLSchema#string

Peter Mulders

http://www.w3.org/2001/XMLSchema#string

Stephan Zbinden

http://www.w3.org/2001/XMLSchema#string

Tim Eisen

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

P304

93-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR511

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Caroline Robert

Bernard Escudier

P577

2012-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221738473

http://www.w3.org/2001/XMLSchema#string

P698

22235142

http://www.w3.org/2001/XMLSchema#string